Risk factors for incident diabetes mellitus among HIV-infected patients receiving combination antiretroviral therapy in Taiwan: A case-control study

HIV Medicine

Volumn 10, Issue 5, 2009, Pages 302-309

  Lo, Y C ^a   Chen, M Y ^b   Sheng, W H ^b   Hsieh, S M ^b   Sun, H Y ^b   Liu, W C ^b   Wu, P Y ^b   Wu, C H ^b   Hung, Chien Ching ^b   Chang, S C ^b  

^a CENTER FOR DISEASE CONTROL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Antiretroviral therapy; Case control study; Diabetes mellitus; HIV infection

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; ATAZANAVIR; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

ADOLESCENT; ADULT; ARTICLE; CASE CONTROL STUDY; CD4 LYMPHOCYTE COUNT; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EXPOSURE; FAMILY HISTORY; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MORBIDITY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; TAIWAN; VIRUS TRANSMISSION;

ADOLESCENT; ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; CHINA; DIABETES MELLITUS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; EPIDEMIOLOGIC METHODS; FAMILY HEALTH; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; TAIWAN; YOUNG ADULT; ZIDOVUDINE;

EID: 65449131159     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2008.00687.x     Document Type: Article

References (35)

1. Palella FJ, Delaney KM, Moorman AC et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338: 853-860.
2. Sterne JAC, Hernán MA, Ledergerber B et al. Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: A prospective cohort study. Lancet 2005; 366: 378-384.
3. Hadigan C, Meigs JB, Corcoran C et al. Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy. Clin Infect Dis 2001; 32: 130-139.
4. Yarasheski KE, Tebas P, Sigmund C et al. Insulin resistance in HIV protease inhibitor-associated diabetes. J Acquir Immune Defic Syndr 1999; 21: 209-216.
5. Carr A, Samaras K, Burton S et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998; 12: F51-F58.
6. Friis-Møller N, Reiss P, Sabin CA et al. for the D:A:D Study Group. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 2007; 356: 1723-1735.
7. Carr A, Samaras K, Chisholm DJ, Cooper DA. Pathogenesis of HIV-1: protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet 1998; 351: 1881-1883.
8. Walli R, Herfort O, Michl GM et al. Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1-infected patients. AIDS 1998; 12: F167-F173.
9. Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA. Diagnosis, prediction, and natural course of HIV-1: Protease inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: A cohort study. Lancet 1999; 353: 2093-2099.
10. Justman JE, Benning L, Danoff A et al. Protease inhibitor use and the incidence of diabetes mellitus in a large cohort of HIV-infected women. J Acquir Immune Defic Syndr 2003; 32: 298-302.
11. Brown TT, Cole SR, Li X et al. Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the Multicenter AIDS Cohort Study. Arch Intern Med 2005; 165: 1179-1184.
12. Ledergerber B, Furrer H, Rickenbach M et al. Factors associated with the incidence of type 2 diabetes mellitus in HIV-infected participants in the Swiss Cohort Study. Clin Infect Dis 2007; 45: 111-119.
13. Tien PC, Schneider MF, Cole SR et al. Antiretroviral therapy exposure and incidence of diabetes mellitus in the Women's Interagency HIV Study. AIDS 2007; 21: 1739-1745.
14. De Wit S, Sabin CA, Weber R et al. Incidence and risk factors for new-onset diabetes in HIV-infected patients: The Data collection on Adverse events of anti-HIV Drugs (D:A:D) Study. Diabetes Care 2008; 31: 1224-1229.
15. Yoon C, Gulick RM, Hoover DR, Vaamonde CM, Glesby MJ. Case-control study of diabetes mellitus in HIV-infected patients. J Acquir Immune Defic Syndr 2004; 37: 1464-1469.
16. Hung CC, Chen MY, Hsieh SM, Sheng WH, Chang SC. Clinical spectrum, morbidity, and mortality of acquired immunodeficiency syndrome in Taiwan: A 5-year prospective study. J Acquir Immune Defic Syndr 2000; 24: 378-385.
17. Hung CC, Hsiao CF, Chen MY et al. Improved survival of persons with human immunodeficiency virus type 1 infection in the era of highly active antiretroviral therapy in Taiwan. Jpn J Infect Dis 2006; 59: 222-228.
18. Yang CH, Huang YF, Hsiao CF et al. Trends of mortality and causes of death among HIV-infected patients in Taiwan, 1984-2005. HIV Med 2008; 9: 535-543.
19. Tseng CH, Tseng CP, Chong CK et al. Increasing incidence of diagnosed type 2 diabetes in Taiwan: Analysis of data from a national cohort. Diabetologia 2006; 49: 1755-1760.
20. Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. Nature 2001; 414: 782-787.
21. Shai I, Jiang R, Manson JE et al. Ethnicity, obesity, and risk of type 2 diabetes in women: A 20-year follow-up study. Diabetes Care 2006; 29: 1585-1590.
22. Sone H, Ito H, Ohashi Y, Akanuma Y, Yamada N and the Japan Diabetes Complication Study Group. Obesity and type 2 diabetes in Japanese patients. Lancet 2003; 361: 85.
23. Aekplakorn W, Stolk RP, Neal B et al. The prevalence and management of diabetes in Thai adults: The international collaborative study of cardiovascular disease in Asia. Diabetes Care 2003; 26: 2758-2763.
24. Hu D, Xie J, Fu P et al. Central rather than overall obesity is related to diabetes in the Chinese population: The InterASIA Study. Obesity 2007; 15: 2809-2816.
25. van der Valk M, Bisschop PH, Romijn JA et al. Lipodystrophy in HIV-1-positive patients is associated with insulin resistance in multiple metabolic pathways. AIDS 2001; 15: 2093-2100.
26. Fleischman A, Johnsen S, Systrom DM et al. Effects of a nucleoside reverse transcriptase inhibitor, stavudine, on glucose disposal and mitochondrial function in muscle of healthy adults. Am J Physiol Endocrinol Metab 2007; 292: E1666-E1673.
27. Blümer RM, van Vonderen MG, Sutinen J et al. Zidovudine/lamivudine contributes to insulin resistance within 3 months of starting combination antiretroviral therapy. AIDS 2008; 22: 227-236.
28. Lactic Acidosis International Study Group. Risk factors for lactic acidosis and severe hyperlactataemia in HIV-1-infected adults exposed to antiretroviral therapy. AIDS 2007; 21: 2455-2464.
29. Wester CW, Okezie OA, Thomas AM et al. Higher-than-expected rates of lactic acidosis among highly active antiretroviral therapy-treated women in Botswana: Preliminary results from a large randomized clinical trial. J Acquir Immune Defic Syndr 2007; 46: 318-322.
30. Sheng WH, Hsieh SM, Lee SC et al. Fatal lactic acidosis associated with highly active antiretroviral therapy in patients with advanced human immunodeficiency virus infection in Taiwan. Int J STD AIDS 2004; 15: 249-253.
31. Hung CC, Shih TTF, Chen MY et al. Longitudinal follow-up study of bone mineral density of HIV-infected patients treated with highly active antiretroviral therapy. 15th International AIDS Congress. Bangkok, Thailand, July 2004 [Abstract WePeB5860].
32. Galli M, Cozzi-Lepri A, Ridolfo AL et al. Incidence of adipose tissue alterations in first-line antiretroviral therapy: The LipoICoNa Study. Arch Intern Med 2002; 162: 2621-2628.
33. Heath KV, Hogg RS, Singer J et al. Antiretroviral treatment patterns and incident HIV-associated morphologic and lipid abnormalities in a population-based cohort. J Acquir Immun Defic Syndr 2002; 30: 440-447.
34. Martinez E, Conget I, Lozano L, Casamitjana R, Gatell JM. Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine. AIDS 1999; 13: 805-810.
35. Walli RK, Michl GM, Bogner JR, Goebel FD. Improvement of HAART-associated insulin resistance and dyslipidemia after replacement of protease inhibitors with abacavir. Eur J Med Res 2001; 6: 413-421.